This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
MORRIS PLAINS, N.J., March 24, 2011 (GLOBE NEWSWIRE) --
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that 3 US patents were awarded.
US Patent 7,910,103 issued on March 22, 2010, with claims covering the treatment of a B-cell malignancy with a therapeutic comprising a human, humanized or chimeric anti-CD22 monoclonal antibody conjugated with a drug or radioisotope, and used in combination with an unconjugated (naked) anti-CD20 antibody. This includes any anti-CD22 antibody, such as the Company's epratuzumab, conjugated with an anticancer drug or therapeutic radionuclide, combined with an anti-CD20 antibody, such as rituximab or veltuzumab. This patent is due to expire in October, 2020.
Immunomedics is conducting clinical trials of epratuzumab labeled with the therapeutic radionuclide, yttrium-90, combined with veltuzumab in patients with aggressive non-Hodgkin lymphoma (NHL), while an investigator-initiated trial is studying this combination in patients with indolent NHL. The Company also has preclinical studies underway with epratuzumab conjugated with the topoisomerase-I inhibitor, SN-38 (derived from the prodrug, irinotecan) in experimental models of NHL, both alone and in combination with veltuzumab. Veltuzumab is the Company's proprietary, humanized, anti-CD20 monoclonal antibody that has completed a Phase I/II clinical trial in non-Hodgkin lymphoma patients, and is currently being studied in patients with chronic lymphocytic leukemia, as well as immune thrombocytopenia.
US Patent 7,919,087 will issue on April 5, 2011, covering a method of treating CD74-positive multiple myeloma with its anti-CD74 humanized monoclonal antibody, milatuzumab, either alone or conjugated with an anticancer drug. This patent is due to expire in March, 2023.
Immunomedics has been conducting clinical trials of milatuzumab alone and conjugated with doxorubicin in the treatment of patients with relapsed multiple myeloma.
US Patent 7,919,090 will issue on April 5, 2011, encompassing claims for treating carcinoembryonic antigen (CEA)-expressing cancers, wherein a specific anti-CEACAM5 monoclonal antibody or fragment thereof is given in combination with a cancer therapeutic agent, such as a drug, radionuclide, toxin, immunomodulator, photoactive agent, immunoconjugate, hormone, or any combinations thereof. Typical anticancer drugs that can be used in combination with this antibody are vincristine, doxorubicin, cyclophosphamide, irinotecan, oxaliplatin, gemcitabine, and 5-fluorouracil/leucovorin. The patent also provides for the anti-CEA antibody to be used in combination with other anti-cancer antibodies, such as anti-VEGF, anti-HER2/neu, and the Company's anti-mucin antibody, PAM4, being studied in pancreatic cancer patients. These other antibodies can be given as unconjugated (naked) antibodies, or conjugated with drugs. This patent is scheduled to expire in October, 2022.